466 related articles for article (PubMed ID: 33205423)
1. Impact of Physiologically Based Pharmacokinetics, Population Pharmacokinetics and Pharmacokinetics/Pharmacodynamics in the Development of Antibody-Drug Conjugates.
Li C; Chen SC; Chen Y; Girish S; Kaagedal M; Lu D; Lu T; Samineni D; Jin JY
J Clin Pharmacol; 2020 Oct; 60 Suppl 1(Suppl 1):S105-S119. PubMed ID: 33205423
[TBL] [Abstract][Full Text] [Related]
2. Application of Pharmacokinetic-Pharmacodynamic Modeling and Simulation for Antibody-Drug Conjugate Development.
Singh AP; Shin YG; Shah DK
Pharm Res; 2015 Nov; 32(11):3508-25. PubMed ID: 25666843
[TBL] [Abstract][Full Text] [Related]
3. Clinical pharmacology strategies in supporting drug development and approval of antibody-drug conjugates in oncology.
Liu SN; Li C
Cancer Chemother Pharmacol; 2021 Jun; 87(6):743-765. PubMed ID: 33792763
[TBL] [Abstract][Full Text] [Related]
4. Informing Development of Bispecific Antibodies Using Physiologically Based Pharmacokinetic-Pharmacodynamic Models: Current Capabilities and Future Opportunities.
Gibbs JP; Yuraszeck T; Biesdorf C; Xu Y; Kasichayanula S
J Clin Pharmacol; 2020 Oct; 60 Suppl 1():S132-S146. PubMed ID: 33205425
[TBL] [Abstract][Full Text] [Related]
5. Transitioning from Basic toward Systems Pharmacodynamic Models: Lessons from Corticosteroids.
Ayyar VS; Jusko WJ
Pharmacol Rev; 2020 Apr; 72(2):414-438. PubMed ID: 32123034
[TBL] [Abstract][Full Text] [Related]
6. Antibody-Drug Conjugates: Pharmacokinetic/Pharmacodynamic Modeling, Preclinical Characterization, Clinical Studies, and Lessons Learned.
Hedrich WD; Fandy TE; Ashour HM; Wang H; Hassan HE
Clin Pharmacokinet; 2018 Jun; 57(6):687-703. PubMed ID: 29188435
[TBL] [Abstract][Full Text] [Related]
7. Application of a PK-PD Modeling and Simulation-Based Strategy for Clinical Translation of Antibody-Drug Conjugates: a Case Study with Trastuzumab Emtansine (T-DM1).
Singh AP; Shah DK
AAPS J; 2017 Jul; 19(4):1054-1070. PubMed ID: 28374319
[TBL] [Abstract][Full Text] [Related]
8. Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics.
Sukumaran S; Zhang C; Leipold DD; Saad OM; Xu K; Gadkar K; Samineni D; Wang B; Milojic-Blair M; Carrasco-Triguero M; Rubinfeld B; Fielder P; Lin K; Ramanujan S
AAPS J; 2017 Jan; 19(1):130-140. PubMed ID: 27679517
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics/pharmacodynamics model-supported early drug development.
Chen B; Dong JQ; Pan WJ; Ruiz A
Curr Pharm Biotechnol; 2012 Jun; 13(7):1360-75. PubMed ID: 22201585
[TBL] [Abstract][Full Text] [Related]
10. Development of a Physiologically-Based Pharmacokinetic Model for Whole-Body Disposition of MMAE Containing Antibody-Drug Conjugate in Mice.
Chang HP; Li Z; Shah DK
Pharm Res; 2022 Jan; 39(1):1-24. PubMed ID: 35044590
[TBL] [Abstract][Full Text] [Related]
11. Evolution of the Systems Pharmacokinetics-Pharmacodynamics Model for Antibody-Drug Conjugates to Characterize Tumor Heterogeneity and
Singh AP; Seigel GM; Guo L; Verma A; Wong GG; Cheng HP; Shah DK
J Pharmacol Exp Ther; 2020 Jul; 374(1):184-199. PubMed ID: 32273304
[TBL] [Abstract][Full Text] [Related]
12. Platform model describing pharmacokinetic properties of vc-MMAE antibody-drug conjugates.
Kågedal M; Gibiansky L; Xu J; Wang X; Samineni D; Chen SC; Lu D; Agarwal P; Wang B; Saad O; Koppada N; Fine BM; Jin JY; Girish S; Li C
J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):537-548. PubMed ID: 28918591
[TBL] [Abstract][Full Text] [Related]
13. Challenges and advances in the assessment of the disposition of antibody-drug conjugates.
Kamath AV; Iyer S
Biopharm Drug Dispos; 2016 Mar; 37(2):66-74. PubMed ID: 25904406
[TBL] [Abstract][Full Text] [Related]
14. Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates.
Sapra P; Betts A; Boni J
Expert Rev Clin Pharmacol; 2013 Sep; 6(5):541-55. PubMed ID: 23978126
[TBL] [Abstract][Full Text] [Related]
15. Application of pharmacokinetics-pharmacodynamics/clinical response modeling and simulation for biologics drug development.
Zhao L; Shang EY; Sahajwalla CG
J Pharm Sci; 2012 Dec; 101(12):4367-82. PubMed ID: 23018763
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic considerations for antibody drug conjugates.
Lin K; Tibbitts J
Pharm Res; 2012 Sep; 29(9):2354-66. PubMed ID: 22740180
[TBL] [Abstract][Full Text] [Related]
17. Minimal physiologically-based pharmacokinetic modeling of DSTA4637A, A novel THIOMAB™ antibody antibiotic conjugate against Staphylococcus aureus, in a mouse model.
Wang-Lin SX; Zhou C; Kamath AV; Hong K; Koppada N; Saad OM; Carrasco-Triguero M; Khojasteh C; Deng R
MAbs; 2018 Oct; 10(7):1131-1143. PubMed ID: 30081725
[TBL] [Abstract][Full Text] [Related]
18. Tools for predicting the PK/PD of therapeutic proteins.
Diao L; Meibohm B
Expert Opin Drug Metab Toxicol; 2015 Jul; 11(7):1115-25. PubMed ID: 25936400
[TBL] [Abstract][Full Text] [Related]
19. Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin.
Shah DK; Haddish-Berhane N; Betts A
J Pharmacokinet Pharmacodyn; 2012 Dec; 39(6):643-59. PubMed ID: 23151991
[TBL] [Abstract][Full Text] [Related]
20. Capturing the Magic Bullet: Pharmacokinetic Principles and Modeling of Antibody-Drug Conjugates.
Zuo P
AAPS J; 2020 Aug; 22(5):105. PubMed ID: 32767003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]